Efficacies of ceftobiprole medocaril and comparators in a rabbit model of osteomyelitis due to methicillin-resistant Staphylococcus aureus.
about
Pharmacokinetics and Dosing of Ceftobiprole Medocaril for the Treatment of Hospital- and Community-Acquired Pneumonia in Different Patient PopulationsA phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumoniaEmerging agents to combat complicated and resistant infections: focus on ceftobiproleComparison of Borate Bioactive Glass and Calcium Sulfate as Implants for the Local Delivery of Teicoplanin in the Treatment of Methicillin-Resistant Staphylococcus aureus-Induced Osteomyelitis in a Rabbit ModelCeftobiprole efficacy in vitro against Panton-Valentine leukocidin production and in vivo against community-associated methicillin-resistant Staphylococcus aureus osteomyelitis in rabbitsCeftobiprole: first cephalosporin with activity against methicillin-resistant Staphylococcus aureus.Ceftobiprole: a new cephalosporin for the treatment of skin and skin structure infections.Daptomycin, fosfomycin, or both for treatment of methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model.Evaluation of ceftobiprole activity against a variety of gram-negative pathogens, including Escherichia coli, Haemophilus influenzae (β-lactamase positive and β-lactamase negative), and Klebsiella pneumoniae, in a rabbit meningitis model.Vancomycin containing PLLA/β-TCP controls experimental osteomyelitis in vivo.Ceftobiprole: First reported experience in osteomyelitis.Efficacy of fosfomycin in experimental osteomyelitis due to methicillin-resistant Staphylococcus aureus.Ceftobiprole medocaril is an effective treatment against methicillin-resistant Staphylococcus aureus (MRSA) mediastinitis in a rat model.
P2860
Q28066877-95881767-10C1-4AF1-8C57-B25183204863Q34414748-83DFA4E5-F599-4FD2-BF9E-2260F65D0292Q35026567-72D601BA-5721-4972-8709-B7DAC46347C0Q36290681-24F1B219-4F72-48F0-B43F-85CACFACAC75Q36396146-C658ED95-5EA4-4B6C-AE99-7A626F7B3E2BQ37461413-B7378CD1-E644-46EE-A599-C81A2DB3888EQ37593094-42AEFCC0-8AC2-48F2-84B6-D2EA0C41939AQ38725968-11A6B805-0A55-487A-B366-0AEF19882C3FQ40600643-117B3AA5-3E64-41D9-AADB-CB95B574DD57Q41656732-85F722EA-D8C1-4046-9514-A9BABCB11D26Q42412528-CCCB35CB-3416-48A8-AD0E-E153C525040AQ42582994-0D71EC91-6F4C-4C82-83AC-47069BF2484FQ43993247-BCA7D75B-FBA5-4AC9-8AE9-2C198FC6874D
P2860
Efficacies of ceftobiprole medocaril and comparators in a rabbit model of osteomyelitis due to methicillin-resistant Staphylococcus aureus.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Efficacies of ceftobiprole med ...... sistant Staphylococcus aureus.
@en
Efficacies of ceftobiprole med ...... sistant Staphylococcus aureus.
@nl
type
label
Efficacies of ceftobiprole med ...... sistant Staphylococcus aureus.
@en
Efficacies of ceftobiprole med ...... sistant Staphylococcus aureus.
@nl
prefLabel
Efficacies of ceftobiprole med ...... sistant Staphylococcus aureus.
@en
Efficacies of ceftobiprole med ...... sistant Staphylococcus aureus.
@nl
P2093
P2860
P356
P1476
Efficacies of ceftobiprole med ...... sistant Staphylococcus aureus.
@en
P2093
Anne Schmitt-Hoffmann
Jacob K Thomas
Jason H Calhoun
Li-Yan Yin
Stuart Shapiro
P2860
P304
P356
10.1128/AAC.00638-07
P407
P577
2008-03-10T00:00:00Z